A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

Inclusion Criteria
Patients must be enrolled on Project: Every Child (APEC14B1) prior to treatment and enrollment on AALL1231
Patients must have newly diagnosed T-lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma (T-LLy) stages II-IV
Exclusion Criteria
Patients must not have received any cytotoxic chemotherapy for either the current diagnosis of T-ALL, T-L-Ly or for any cancer diagnosis prior to the initiation of protocol therapy on AALL1231
Uncontrolled seizure disorder
Diagnosis of Down syndrome (Trisomy 21)
Patients who are pregnant
Lactating females who plan to breastfeed
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
Patient has hypersensitivity to bortezomib, boron, or mannitol
Serious medical or psychiatric illness likely to interfere with participation in this clinical study
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and within 30 days of any dose of bortezomib